TY - JOUR
T1 - Atomoxetine
T2 - A selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder
AU - Kratochvil, Christopher J.
AU - Vaughan, Brigette S.
AU - Harrington, Martin J.
AU - Burke, William J.
PY - 2003/7/1
Y1 - 2003/7/1
N2 - Atomoxetine (Strattera™, Eli Lilly & Co.) is a selective noradrenaline reuptake inhibitor that has been studied for use in the treatment of attention-deficit/hyperactivity disorder (ADHD). So far, two open-label and seven randomised, double-blind, placebo-controlled, clinical trials have been published, six in youths and three in adults. Each of these trials has shown a positive response as measured by the primary efficacy measures, the ADHD-IV Rating Scale (ADHD RS) or the Conners Adult ADHD Rating Scale (CAARS). Atomoxetine has generally been well tolerated. In November of 2002 the FDA approved atomoxetine for use in the US for the treatment of ADHD in children, adolescents and adults. Atomoxetine is the first nonstimulant approved by the FDA for the treatment of ADHD and the first medication approved for the treatment of adult ADHD.
AB - Atomoxetine (Strattera™, Eli Lilly & Co.) is a selective noradrenaline reuptake inhibitor that has been studied for use in the treatment of attention-deficit/hyperactivity disorder (ADHD). So far, two open-label and seven randomised, double-blind, placebo-controlled, clinical trials have been published, six in youths and three in adults. Each of these trials has shown a positive response as measured by the primary efficacy measures, the ADHD-IV Rating Scale (ADHD RS) or the Conners Adult ADHD Rating Scale (CAARS). Atomoxetine has generally been well tolerated. In November of 2002 the FDA approved atomoxetine for use in the US for the treatment of ADHD in children, adolescents and adults. Atomoxetine is the first nonstimulant approved by the FDA for the treatment of ADHD and the first medication approved for the treatment of adult ADHD.
KW - Atomoxetin
KW - Attention-deficit/hyperactivity disorder
KW - Nonstimulant
KW - Noradrenaline
UR - http://www.scopus.com/inward/record.url?scp=0037768960&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037768960&partnerID=8YFLogxK
U2 - 10.1517/14656566.4.7.1165
DO - 10.1517/14656566.4.7.1165
M3 - Article
C2 - 12831341
AN - SCOPUS:0037768960
SN - 1465-6566
VL - 4
SP - 1165
EP - 1174
JO - Expert Opinion on Pharmacotherapy
JF - Expert Opinion on Pharmacotherapy
IS - 7
ER -